Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration | Zendy

Valentin Fuhrmann | Zendy; Peter Schenk | Zendy; Walter Jaeger | Zendy; Salwa Ahmed | Zendy; Florian Thalhammer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration

Author(s) -

Valentin Fuhrmann,

Peter Schenk,

Walter Jaeger,

Salwa Ahmed,

Florian Thalhammer

Publication year - 2004

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkh421

Subject(s) - moxifloxacin , medicine , pharmacokinetics , extracorporeal , renal replacement therapy , sepsis , critically ill , intensive care medicine , intensive care , respiratory failure , antibiotics , anesthesia , pharmacology , microbiology and biotechnology , biology

Moxifloxacin is an 8-methoxy quinolone with a broad range of activity against clinically important pathogens. Therefore it is frequently administered in severe respiratory tract infections. Continuous venovenous haemodiafiltration (CVVHDF) is an important extracorporeal renal replacement therapy for intensive care patients suffering from sepsis and multiple organ failure. The aim of this study was to investigate the pharmacokinetics of intravenous moxifloxacin in anuric critically ill patients undergoing CVVHDF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research